OncoMatch/Clinical Trials/NCT06223542
Studying TAK-243 in Patients With Advanced Cancer
Is NCT06223542 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies UAE Inhibitor TAK-243 for advanced lymphoma.
Treatment: UAE Inhibitor TAK-243 — This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) and in patients with lymphoma. TAK-243 is a drug that binds to and inhibits the ubiquitin-activating enzyme, an enzyme that is more active on cancer cells than healthy cells, inhibiting tumor cell proliferation and survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard-of-care or approved therapies known to confer clinical benefit — solid tumor
solid tumors with relapsed or refractory disease who have received standard-of-care or approved therapies known to confer clinical benefit
Must have received: lymphoma-directed therapy — aggressive lymphoma
patients with aggressive lymphomas who have received 2 prior lines of lymphoma-directed therapy and who do not have remaining effective treatment options (including transplant)
Lab requirements
Blood counts
Hemoglobin >= 9 g/dL (patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed); Absolute neutrophil count >= 1,000/mcL; Platelets >= 75,000/mcL
Kidney function
Creatinine <= 1.5 x institutional ULN OR creatinine clearance >= 60 mL/min/1.73 m^2 by Cockcroft-Gault
Liver function
Total bilirubin <= 1.5 x institutional ULN; AST/ALT <= 3 x institutional ULN OR <= 5 x institutional ULN for patients with liver metastases at baseline
Hemoglobin >= 9 g/dL (patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed) Absolute neutrophil count >= 1,000/mcL Platelets >= 75,000/mcL Total bilirubin <= 1.5 x institutional upper limit of normal (ULN) AST/ALT <= 3 x institutional ULN OR <= 5 x institutional ULN for patients with liver metastases at baseline Creatinine <= 1.5 x institutional ULN OR creatinine clearance >= 60 mL/min/1.73 m^2 by Cockcroft-Gault
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Cancer Institute Developmental Therapeutics Clinic · Bethesda, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify